Golden-Mason Golden-Mason

Prof. Golden-Mason Golden-Mason

Gastroenterology/Liver, University of Southern California, Los Angeles, California, USA
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Immunity
Verified
Journal Article
Closed access
ECEric L. Campbell
Eric L. Campbell
WBWalter J. Bruyninckx
Walter J. Bruyninckx
CKCaleb J. Kelly
Caleb J. Kelly
LGLouise E. Glover
Louise E. Glover
EMEóin N. McNamee
Eóin N. McNamee
SCSean P. Colgan
Sean P. Colgan

15 September 2009 in Journal of Virology
Verified
Journal Article
Closed access
Golden-Mason Golden-MasonGolden-Mason Golden-Mason
Golden-Mason Golden-Mason
BPBrent E. Palmer
Brent E. Palmer
NKNasim Kassam
Nasim Kassam
LTLisa Townshend-Bulson
Lisa Townshend-Bulson
SLStephen Livingston
Stephen Livingston
HRHugo R. Rosen
Hugo R. Rosen
A number of emerging molecules and pathways have been implicated in mediating the T-cell exhaustion characteristic of chronic viral infection. Not all dysfunctional T cells express PD-1, nor are they all rescued by blockade of the PD-1/PD-1 ligand pathway. In this study, we characterize the expression of T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3) in chronic hepatitis C infection. For the first time, we found that Tim-3 expression is increased on CD4 + and CD8 + T cells in chronic hepatitis C virus (HCV) infection. The proportion of dually PD-1/Tim-3-expressing cells is greatest in liver-resident T cells, significantly more so in HCV-specific than in cytomegalovirus-specific cytotoxic T lymphocytes. Tim-3 expression correlates with a dysfunctional and senescent phenotype (CD127 low CD57 high ), a central rather than effector memory profile (CD45RA negative CCR7 high ), and reduced Th1/Tc1 cytokine production. We also demonstrate the ability to enhance T-cell proliferation and gamma interferon production in response to HCV-specific antigens by blocking the Tim-3-Tim-3 ligand interaction. These findings have implications for the development of novel immunotherapeutic approaches to this common viral infection.

1 September 2007 in Journal of Virology
Verified
Journal Article
Closed access
Golden-Mason Golden-MasonGolden-Mason Golden-Mason
Golden-Mason Golden-Mason
BPBrent Palmer
Brent Palmer
JKJared Klarquist
Jared Klarquist
JMJohn A. Mengshol
John A. Mengshol
NCNicole Castelblanco
Nicole Castelblanco
HRHugo R. Rosen
Hugo R. Rosen
Infection with hepatitis C virus (HCV) is associated with persistence in the majority of individuals. We demonstrate here that the inhibitory molecule programmed death-1 (PD-1) is significantly upregulated on total and HCV-specific CD8+cytotoxic T lymphocytes (CTLs) in the peripheral blood and livers of patients with chronic infection compared to subjects with spontaneous HCV resolution, patients with nonviral liver disease, and normal controls. PD-1 expression on cytomegalovirus-specific CTLs also varies according to HCV status and is highest in patients with chronic infection. HCV-specific CTLs that are PD-1highexpress higher levels of the senescence marker CD57 than PD-1lowCTLs, and CD57 expression is greater in chronic than in resolved infection. In vitro blockade of PD-1 by monoclonal antibodies specific to its ligands (PD-L1 and PD-L2) results in restoration of functional competence (proliferation and gamma interferon and interleukin-2 secretion) of HCV-specific CTLs, including those residing in the liver. This reversal of CTL exhaustion is evident even in individuals who lack HCV-specific CD4+T-cell help. Our data indicate that the PD-1/PD-L pathway is critical in persistent HCV infection in humans and represents a potential novel target for restoring function of exhausted HCV-specific CTLs.

1 December 2010 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
RMRachel H. McMahan
Rachel H. McMahan
Golden-Mason Golden-MasonGolden-Mason Golden-Mason
Golden-Mason Golden-Mason
MNMichael I. Nishimura
Michael I. Nishimura
BMBrian J. McMahon
Brian J. McMahon
MKMichael Kemper
Michael Kemper
HRHugo R. Rosen
Hugo R. Rosen
Having successfully developed mechanisms to evade immune clearance, hepatitis C virus (HCV) establishes persistent infection in approximately 75%–80% of patients. In these individuals, the function of HCV-specific CD8+ T cells is impaired by ligation of inhibitory receptors, the repertoire of which has expanded considerably in the past few years. We hypothesized that the coexpression of the negative regulatory receptors T cell immunoglobulin and mucin domain–containing molecule 3 (Tim-3) and programmed death 1 (PD-1) in HCV infection would identify patients at risk of developing viral persistence during and after acute HCV infection. The frequency of PD-1–Tim-3– HCV-specific CTLs greatly outnumbered PD-1+Tim-3+ CTLs in patients with acute resolving infection. Moreover, the population of PD-1+Tim-3+ T cells was enriched for within the central memory T cell subset and within the liver. Blockade of either PD-1 or Tim-3 enhanced in vitro proliferation of HCV-specific CTLs to a similar extent, whereas cytotoxicity against a hepatocyte cell line that expressed cognate HCV epitopes was increased exclusively by Tim-3 blockade. These results indicate that the coexpression of these inhibitory molecules tracks with defective T cell responses and that anatomical differences might account for lack of immune control of persistent pathogens, which suggests their manipulation may represent a rational target for novel immunotherapeutic approaches.

1 April 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
RMRachel H. McMahan
Rachel H. McMahan
XWXiaoxin X. Wang
Xiaoxin X. Wang
LCLin Ling Cheng
Lin Ling Cheng
TKTibor Krisko
Tibor Krisko
MSMaxwell Smith
Maxwell Smith
HRHugo R. Rosen
Hugo R. Rosen
Nonalcoholic fatty liver disease (NAFLD) affects a large proportion of the American population. The spectrum of disease ranges from bland steatosis without inflammation to nonalcoholic steatohepatitis and cirrhosis. Bile acids are critical regulators of hepatic lipid and glucose metabolism and signal through two major receptor pathways: farnesoid X receptor (FXR), a member of the nuclear hormone receptor superfamily, and TGR5, a G protein-coupled bile acid receptor (GPBAR1). Both FXR and TGR5 demonstrate pleiotropic functions, including immune modulation. To evaluate the effects of these pathways in NAFLD, we treated obese db/db mice with a dual FXR/TGR5 agonist (INT-767) for 6 weeks. Treatment with the agonist significantly improved the histological features of nonalcoholic steatohepatitis. Furthermore, treatment increased the proportion of intrahepatic monocytes with the anti-inflammatory Ly6Clow phenotype and increased intrahepatic expression of genes expressed by alternatively activated macrophages, including CD206, Retnla, and Clec7a. In vitro treatment of monocytes with INT-767 led to decreased Ly6C expression and increased IL-10 production through a cAMP-dependent pathway. Our data indicate that FXR/TGR5 activation coordinates the immune phenotype of monocytes and macrophages, both in vitro and in vivo, identifying potential targeting strategies for treatment of NAFLD.

4 March 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JMJohn A. Mengshol
John A. Mengshol
Golden-Mason Golden-MasonGolden-Mason Golden-Mason
Golden-Mason Golden-Mason
TATomohiro Arikawa
Tomohiro Arikawa
MSMaxwell Smith
Maxwell Smith
TNToshiro Niki
Toshiro Niki
HRHugo R. Rosen
Hugo R. Rosen
Approximately 200 million people throughout the world are infected with hepatitis C virus (HCV). One of the most striking features of HCV infection is its high propensity to establish persistence (∼70–80%) and progressive liver injury. Galectins are evolutionarily conserved glycan-binding proteins with diverse roles in innate and adaptive immune responses. Here, we demonstrate that galectin-9, the natural ligand for the T cell immunoglobulin domain and mucin domain protein 3 (Tim-3), circulates at very high levels in the serum and its hepatic expression (particularly on Kupffer cells) is significantly increased in patients with chronic HCV as compared to normal controls. Galectin-9 production from monocytes and macrophages is induced by IFN-γ, which has been shown to be elevated in chronic HCV infection. In turn, galectin-9 induces pro-inflammatory cytokines in liver-derived and peripheral mononuclear cells; galectin-9 also induces anti-inflammatory cytokines from peripheral but not hepatic mononuclear cells. Galectin-9 results in expansion of CD4+CD25+FoxP3+CD127low regulatory T cells, contraction of CD4+ effector T cells, and apoptosis of HCV-specific CTLs. In conclusion, galectin-9 production by Kupffer cells links the innate and adaptive immune response, providing a potential novel immunotherapeutic target in this common viral infection.